Clinical Trials Logo

Myocardial Infarction clinical trials

View clinical trials related to Myocardial Infarction.

Filter by:

NCT ID: NCT04851418 Recruiting - Clinical trials for Coronary Artery Disease

Pre-hOspital Evaluation of Chest Pain Patients With sUspected Non ST-segment eLevation myocARdial Infarction Using the HEART-score With a Troponin Point-of-care Test

POPular HEART
Start date: September 1, 2020
Phase:
Study type: Observational

Overcrowding in the emergency department is an increasing problem in hospitals worldwide. Point-of-care Troponin (POC cTn) testing combined with a well investigated risk stratification tool (HEART-score) used in the ambulance may contribute to more rapidly diagnostics of ruling in or ruling out myocardial infarctions (MI) and subsequently reduce unnecessary hospital admissions, total admission time and costs. However, the applicability of the POC cTn and the HEART-score in the pre-hospital setting remains unclear. This study will evaluate this applicability.

NCT ID: NCT04844931 Recruiting - Clinical trials for ST Elevation Myocardial Infarction

Remote Ischemic Conditioning With Local Ischemic Postconditioning in High-Risk ST-elevation Myocardial Infarction

RIP-HIGH
Start date: July 5, 2021
Phase: N/A
Study type: Interventional

The RIP-HIGH trial is a two-arm randomized controlled trial aiming to compare the impact of combined remote ischemic conditioning (RIP) and local ischemic postconditioning (PostC) vs. standard of care on clinical outcome in high-risk ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.

NCT ID: NCT04825743 Recruiting - Clinical trials for ST-elevation Myocardial Infarction (STEMI)

A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

CELEBRATE
Start date: April 24, 2021
Phase: Phase 3
Study type: Interventional

This is a Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study. Subjects with STEMI will be enrolled in the ambulance if they meet all eligibility criteria. These subjects will be evaluated by (para)medics who transport the subjects to the participating hospitals in Europe and North America. Hospitals and ambulance services with experience in ambulance studies will be selected. Each subject will receive a single subcutaneous injection containing either zalunfiban Dose 1 (0.110 mg/kg) or zalunfiban Dose 2 (0.130 mg/kg) or placebo

NCT ID: NCT04818918 Recruiting - Clinical trials for Myocardial Infarction

Coronary Flow and Myocardial Viability: the FloVITA Study

FloVita
Start date: May 19, 2021
Phase:
Study type: Observational

Evaluation of fractional flow reserve (FFR) is a key method for assessing ischemia with a view to guiding revascularization strategy following acute coronary syndrome. A stenosis that appears to be severe by angiography may cause limited ischemia (with an FFR value >0.80) due to the incapacity of the necrotic zone to achieve physiological hyperemia, i.e. maximal coronary flow. Recently, it has been demonstrated that absolute coronary flow, and micro- and macrovascular resistance, as measured by a thermodilution technique, using the Rayflow microcatheter (Hexacath) are strongly associated with myocardial mass. In extensive necrosis, there is a loss of myocardial mass, and these tools could be of potential interest in measuring myocardial viability, which reflects the extent of remaining viable myocardial mass. Therefore, this study aims to investigate the relationship between both absolute coronary flow and microvascular resistance, and myocardial viability assessed by MRI. In a prospective, single-centre, interventional study, we will compare absolute coronary flow and microvascular resistance in the left anterior descending artery, in patients with and without a history of ST segment elevation MI.

NCT ID: NCT04817748 Recruiting - Clinical trials for Myocardial Infarction

Metabolomics Characterization of Biomarkers of Different Types of Myocardial Infarction in Different Time.

MCBDTMIDT
Start date: November 17, 2020
Phase:
Study type: Observational

To find new biomarkers through Metabonomics Study of different types of myocardial infarction in Different Time.

NCT ID: NCT04803864 Recruiting - Clinical trials for ST Elevation Myocardial Infarction

Study of Roxadustat in the Treatment of Acute Myocardial Infarction

ROXAMI
Start date: June 10, 2021
Phase: Phase 2
Study type: Interventional

Depite successful primary percutaneous coronary intervention (PCI) and standardized medical treatment, prognosis of acute ST-elevation myocardial infarction patents are still a poor, with high morality and various complications such as heart failure. Roxadustat is a new drug targeting hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibition and has shown promising effect in reducing infarct size in pre-clinical studies. This study aims to evaluate the efficacy and safety of early and short-term administration of roxadustat in the treatment of acute ST-elevation myocardial infarction.

NCT ID: NCT04793425 Recruiting - Telemedicine Clinical Trials

Mobile App and Digital System for Patients After Myocardial Infarction

afterAMI
Start date: December 1, 2020
Phase: N/A
Study type: Interventional

The treatment of acute myocardial infarction (MI) in Poland is at the level of standardized European care. However, the first months after MI are crucial from the perspective of patient's prognosis. It is extremely important to take care of all cardiovascular risk factors. Mobile application (afterAMI) supported by web system is a novel telemedical tool created to support patient and physician during the process of cardiac rehabilitation. The application has educational model with focus on cardiovascular risk factors and lifestyle after MI. Moreover, there is a module to control vital signs like blood pressure, heart rate, weight and many others. Additionally, application will send reminders for better drug adherence. 100 patients will be recruited to take part in the study. All of which will be hospitalized at the 1st Department and Clinic of Cardiology because of the MI. The aim of the project is to study the impact of application-supported model of care with comparison to standard care. At the end of the study cardiovascular risk factors control will be analysed, as well as rehospitalizations, patient's knowledge regarding risk factors, return to work and quality of life. This will be a prospective, open-label, randomized, single-centre study. All 100 patients will be observed 6 months after discharge from the hospital. End points will be assessed during control visit 1- and 6-months after inclusion into the study. This project is an example of a telemedicine solution application into everyday practice, which is consistent with multiple international cardiac societies.

NCT ID: NCT04789317 Recruiting - Clinical trials for Non ST Elevation Myocardial Infarction

Pullback Pressure Gradient (PPG) Global Registry

PPG Global
Start date: December 23, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to determine the predictive capacity of the Pullback Pressure Gradient (PPG) index for post-PCI FFR and to determine the impact of the PPG index on clinical decision making about revascularization and on clinical outcomes.

NCT ID: NCT04788940 Recruiting - Clinical trials for Acute Myocardial Infarction

Clinical Implication CMR in AMI Registry

CMR-AMI
Start date: March 8, 2021
Phase:
Study type: Observational

1. To evaluate the clinical implication of cardiac magnetic resonance imaging in patients with acute myocardial infarction 2. To determine factors affecting the 6-month remodeling index assessed by cardiac magnetic resonance imaging

NCT ID: NCT04788186 Recruiting - Clinical trials for Coronary Artery Disease

Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial).

BEEFBURGER
Start date: August 23, 2021
Phase: Phase 4
Study type: Interventional

Beta-blockers have the greatest cardiovascular impact in patients with reduced heart function/heart failure and in reducing the peri-operative risk of atrial fibrillation. In patients without these high-risk features treated with coronary artery bypass graft (CABG) surgery, their continued long-term role is unclear.